231 related articles for article (PubMed ID: 14767265)
1. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.
Schwaab T; Tretter C; Gibson JJ; Cole BF; Schned AR; Harris R; Wallen EM; Fisher JL; Waugh MG; Truman D; Stempkowski LM; Crosby NA; Heaney J; Ernstoff MS
J Urol; 2004 Mar; 171(3):1036-42. PubMed ID: 14767265
[TBL] [Abstract][Full Text] [Related]
2. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
3. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
6. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
7. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
9. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines.
Inoue H; Iga M; Nabeta H; Yokoo T; Suehiro Y; Okano S; Inoue M; Kinoh H; Katagiri T; Takayama K; Yonemitsu Y; Hasegawa M; Nakamura Y; Nakanishi Y; Tani K
Cancer Sci; 2008 Nov; 99(11):2315-26. PubMed ID: 18957055
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis.
Repmann R; Goldschmidt AJ; Richter A
Anticancer Res; 2003; 23(2A):969-74. PubMed ID: 12820332
[TBL] [Abstract][Full Text] [Related]
11. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
Doehn Ch; Richter A; Lehmacher W; Jocham D
Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
15. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
17. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
18. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma.
Powell A; Creaney J; Broomfield S; Van Bruggen I; Robinson B
Lung Cancer; 2006 May; 52(2):189-97. PubMed ID: 16563560
[TBL] [Abstract][Full Text] [Related]
19. Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.
Hueman MT; Stojadinovic A; Storrer CE; Dehqanzada ZA; Gurney JM; Shriver CD; Ponniah S; Peoples GE
Cancer Immunol Immunother; 2007 Feb; 56(2):135-46. PubMed ID: 16783576
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats.
Djalilian HR; Caicedo E; Lessan K; Grami V; Le CT; Spellman SR; Pambuccian S; Hall WA; Low WC; Ondrey FG
Cancer Immunol Immunother; 2007 Aug; 56(8):1207-14. PubMed ID: 17219150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
